Christopher Lloyd
Director AstraZeneca
Seminars
Wednesday 10th December 2025
Engineering Effector CD8 Biased T-Cell Engagers with TITAN: A Novel TCE Format
1:00 pm
- Bispecific T-cell engagers (TCEs) have shown promising efficacy in the clinic, especially in the context of hematological malignancies but recently also for small cell lung cancer
- However, these treatments are still associated with significant toxicities, including cytokine release syndrome and ICANS, limiting their therapeutic window and potential for clinical combinations
- We developed a novel TCE format, TITAN (Target Induced T-cell Activating Nanobodies), with the potential for an improved therapeutic index by engineering a first-in-class CD8-guided TCE
